On Tuesday, 29 September, after months of human clinical trials, the European Commission gave final marketing authorisation for two pandemic influenza vaccines: Focetria® (Novartis) and Pandemrix® (GlaxoSmithKline).
Lai novērstu šos draudus, Eiropas Komisija devusi atļauju piedāvāt tirgū divas jaunas vakcīnas — Focetria ® ( Novartis ) un Pandemrix ® ( GlaxoSmithKline ).